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with no or mild pain during the follow-up period was obtained by
pregabalin (59.6%;CI95% 59.0%–60.2%); followed by gabap-
entin (49.2%; CI95% 48.7%–49.7%); amitriptyline (47.6%;
CI95% 47.1%–48.1%) and carbamazepine (34.4%; CI95%
34.1%–34.8%). The annual expected mean costs per patient
were US$3001.4 (CI95% US$2956.4–US$3046.3); US$4,707.7
(CI95% US$4689.9–US$4723.6); US$2814.4 (CI95%
US$2783.4–US$2845.5) and US$3701.9 (CI95% US$3687.2–
US$3716.6); respectively following the order above. The ICER’s
of pregabalin vs. carbamazepine (baseline), gabapentin and
amitriptyline were -US$700.5 (CI95% -US$670.4:-US$730.7),
-US$1706.4 (CI95% -US$1677.3:-US$1733.4) and US$186.9
(CI95% US$173.1–US$200.8); respectively. Using acceptability
curves (WTP US$5000–US$50,000), pregabalin showed a prob-
ability between 90–99% to be the treatment most cost-effective.
CONCLUSION: In Mexico, pregabalin showed to be a cost-
saving therapy when is compared with carbamazepine and gaba-
pentin; and cost-effective vs. amitriptyline in the management of
neuropathic pain.
DB3
REAL-WORLD ANALYSIS OF PERCENT OF PATIENTSWITH
TYPE 2 DIABETES ACHIEVING GLYCEMIC GOALWITH
INSULIN GLARGINE
Misurski D1, Schroeder B2,Wade R3, Quimbo R3, Nielsen L2,
Fabunmi R2,Wintle M2
1Eli Lilly and Company, Indianapolis, IN, USA, 2Amylin Pharmaceuticals,
Inc, San Diego, CA, USA, 3HealthCore, Inc,Wilmington, DE, USA
OBJECTIVE: The primary aim of type 2 diabetes (T2D) therapy
is helping patients achieve glycemic goals (A1C < 7%) as recom-
mended by the ADA. In the recent randomized controlled trials
4-T and INITIATE, patients treated with basal insulin alone
achieved goal 28% and 40% of the time, respectively, despite
progressive insulin titration. In this retrospective cohort study
using a large, US commercial health plan claims database, we
describe the clinical effectiveness of newly-prescribed basal
insulin glargine (IG) in insulin-naive patients. METHODS: A
total of 13,154 insulin-naïve (not prescribed insulin in previous
6 mo) patients were identiﬁed with a new prescription claim for
IG between January 1, 2004 and June 30, 2006, 6 mo of
pre-index eligibility (ﬁrst claim = index date), 12 mo of post-
index eligibility, and 18 y old. RESULTS: From this cohort,
7730 (59%) patients had no other insulin claims other than IG in
the entire post-index period. All patients with baseline (100 d
pre-index) and post-index (60–365 d) A1C data available and
baseline A1C7.0% were analyzed (n = 313; mean baseline A1C
(SD) = 9.8  2.1%). Mean (SD) age was 52  8 y (41%
female; 3%65 y). In this cohort of patients who did not add
any additional insulin (n = 313), 27% achieved A1C < 7% in the
post-index period (mean [min,max] time index to post-index
A1C = 238 d [63,365]). Mean (SD) post-index A1C was
8.2  1.9%. CONCLUSION: In this real-world analysis of
patients initiated on IG, the percentage of patients achieving
A1C < 7.0% and mean post-index A1C indicate that most
patients do not achieve recommended glycemic targets—results
which mirror controlled clinical studies. In addition, more than
half of patients initiating IG did not supplement with additional
insulin therapy over the course of the ﬁrst year of therapy, despite
not reaching glycemic goals. Because the contribution of post-
prandial glucose to A1C increases as A1C approaches goal,
agents targeting fasting glucose alone, like IG, may be insufﬁcient
in helping patients with T2D achieve glycemic goals.
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OBJECTIVE: The American Diabetes Association (ADA) recom-
mends metformin as ﬁrst line treatment for T2DM. As diabetes is
a progressive disease, patients will ultimately need additional
therapies to reach glycemic goals. Little information has been
published that describes what happens to patients not optimally
controlled on metformin monotherapy in the real world. We
analyzed monitoring, treatments and outcomes for such patients
using the PHARMetrics® linked laboratory database.
METHODS: An algorithm based on ICD-9 codes and laboratory
test values identiﬁed 1901 T2DM patients who failed metformin
monotherapy between 2000 and 2006. The index date was
deﬁned as the ﬁrst Hba1c test greater than the ADA recom-
mended goal of 7%, after at least 6 months metformin mono-
therapy. The pre-period was deﬁned as two years prior to the
index date. The follow-up period was deﬁned as 12 months after
the index date. Other laboratory test values were obtained during
a +/-30-day window of the index date. Micro- and macro-
vascular diabetes-related complications were identiﬁed using
ICD-9 codes during the pre-period. Subsequent glucose control
and ﬁrst therapy change in the 3 to 12 months of the follow-up
period were also analyzed. RESULTS: A total of 48.5% of the
sample was male. Mean age was 57.9 (11). The prevalence of
diabetic-related complications were as follows: retinopathy
(12.64%); neuropathy (12.13%); nephropathy (2.67%); myo-
cardial infarction (1.31%); stroke (2.82%) and ischemic heart
disease (12.99%). In the follow-up period, 76.5% of patients had
an Hba1c test and only 24.7% were at goal. Only 33% changed
therapy: 19% added on sulfonylurea; 5% switched to a ﬁxed-
dose combination product and 4% added or switched to thiazo-
lidinedione. Overall, the average time from failure until therapy
change was 256.0 days (73.1). CONCLUSION: These results
indicate considerable unmet medical need in treating T2DM.
Glycemic control would have likely been better with additional
pharmaceutical utilization.
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OBJECTIVE: To assess age, racial, and regional differences in
utilization of physician, hospital outpatient and emergency
department services related to stroke over the past six years.
METHODS: This study was a retrospective analysis of the
National Ambulatory Medical Care Survey (NAMCS) and the
National Hospital Ambulatory Medical Care Survey (NHAMCS)
from 2000..C2005. Ischemic stroke related visits in persons aged
45 years were identiﬁed using diagnosis codes (ICD 9 CM)
433.1x, 434.xx, and 436.xx. Visits per/1000 persons were calcu-
lated using United States population estimates. With logistic
regression, we adjusted associations between stroke-related visits
and age, race, and region (Northeast, Midwest, West, and South),
for sex, stroke risk factors, insurance type, and survey year.
RESULTS: From 2000 to 2005, stroke-related ambulatory care
visits increased signiﬁcantly from 8.3/1000 persons to 16.1/1000
persons (P Trend=<0.0001)..Crepresenting a 195% rise in stroke
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related ambulatory care visits over a 6 year period. Although all
age groups demonstrated an increase in stroke-related visit rates
during the study period, the 55–64 year age group had the most
signiﬁcant rise. Among persons aged 55–64 years, stroke-related
visit rates increased from 9.1/1000 persons to 39.1/1000 persons
(P Trend=<0.0001), resulting in a 428% rise. After adjustment,
greater odds of stroke visits were found in persons 55 years
(55–64 years OR = 3.4, 95%CI: 2.3–5.0; 65–74 years OR = 4.1,
95%CI: 2.7–6.2; 75 years OR = 5.4, 95%CI: 3.6–8.2) (age
45–54 referent), blacks (OR = 1.4, 95%CI: 1.0–2.0), men
(OR = 1.5, 95%CI: 1.2–1.9), or persons in the South (OR = 1.6,
95%CI: 1.2–2.1). CONCLUSION: From 2000 to 2005, stroke-
related ambulatory visits increased signiﬁcantly in the United
States, particularly among the near-elderly, Southern residents,
and blacks. These age, regional, and racial disparities in outpatient
stroke utilization are not explained by stroke risk factor preva-
lence. Health care resource allocation needs to target these high-
risk groups.
DU2
DOES COMMUNITY-BASED HEALTH INSURANCE IMPROVE
ACCESSTO DRUGS AND HEALTH CARE FORTHE POOREST
IN AFRICA?
Souares A1, Savadogo G2, Gnawali DP1, Sauerborn R1
1Heidelberg University, Heidelberg, BadenWürttemberg, Germany,
2Centre de Recherche en Santé de Nouna, Nouna, Kossi, Burkina
Faso
OBJECTIVES: Health care utilization in Burkina Faso is far
below the average level in OECD countries (0.15 and eight
contacts per capita and year respectively). Worse still, there is a
pronounced income elasticity of demand. Hence, much of the
potential beneﬁt of effective drugs remains elusive for most of the
sick poor. This paper reports on the enrollment of the poorest
quintile in CBI and the change in health care utilization of the
insured households. Further more, the effect of a targeted subsidy
on enrollment of the poorest 5th of household was assessed.
METHODS: Community-based insurance has been offered to a
district in Burkina Faso, comprising 74,000 people who lived in
53 villages and the district capital of Nouna since 2004. Com-
munity self assessment of poverty was used in 2007 to identify
the poorest quintile of households who were subsequently
offered insurance at half the usual premium rate. RESULTS:
Overall enrollment in health insurance was 5.2% in 2006 and
8.3% in 2007. However, only 1.1% of the poorest quintile of
household chose to enroll. In 2007, with the targeted subsidy on
enrollment of poorest households, this rate reached 11.1%. Once
enrolled, households increased their utilization of health care
substantially (from 0.15 to 0.64 contacts per capita and year).
This increase in utilization given enrollment held also for the
poorest quintile. CONCLUSION: The authors discuss the cova-
riates inﬂuencing household decisions to enroll and to use health
care subsequently. They stress the need to enhance the access of
the poor to drugs and health care in general through the com-
bined effect of community-based insurance and targeted subsi-
dies to the poor.
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OBJECTIVE: To explore the impact of the 2007 southern Cali-
fornia wildﬁres on prescription medication access. METHODS:
CVS Caremark members living within San Diego, LA/Ventura,
Orange, and San Bernardino counties were split into Wildﬁre
(n = 83,479) and non-Wildﬁre (n = 145,325) cohorts using zip
codes with documented wildﬁre activity between October 20 and
November 9, 2007. Weekly pharmacy claims prevalence rates
(prevalence) between July 21, and December 8, 2007 (providing
13 pre-, 3 concurrent, and 4 post-wildﬁre weeks) were derived;
calculated as the number of individuals with paid claim(s)
divided by all eligible individuals. Cohort-speciﬁc prevalence
rates were derived for: Analgesics (GPI 64 to 66), anxiolytics
(57), antidepressants (58), antihyperlipidemics (39), antihyper-
tensives (36), beta-blockers (33), hypnotics (60), migraine (67),
respiratory (41 to 45), anti-ulcer (49), and across all classes.
Weekly deviations from cohort- and class-speciﬁc 20-week mean
prevalence were expressed as percentages. RESULTS: Mean
weekly prevalence was 75/1000 for Wildﬁre and 73/1000 for
non-Wildﬁre cohorts. Overall prevalence was below the mean
for both cohorts during the ﬁrst week of the wildﬁre period
(Wildﬁre: -12.9%, non-Wildﬁre: -4.8%); with the Wildﬁre
cohort experiencing decreases approximately four-fold greater
than the non-Wildﬁre cohort in antidepressants, antihyperlipi-
demics, antihypertensives, two-fold greater in anxiolytics, and
similar for all other classes except for the respiratory class, the
only classwith a prevalence increase relative to themean (Wildﬁre:
10.1%, non-Wildﬁre: 30.8%). During the second week, preva-
lence increased above the mean in all classes among the Wildﬁre
cohort (4% higher overall) but was mixed for the non-Wildﬁre
cohort (0.9% lower overall). Differences for almost every week
before and after the ﬁres were about equal. CONCLUSION:
Natural disasters can have a signiﬁcant affect on access to needed
medications. The wildﬁres in California decreased overall and
class-speciﬁc medication acquisition during the ﬁrst week except
for respiratory medications. The pharmacy system accommo-
dated these localized emergencies well.
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OBJECTIVE: The efﬁcacy of angiotensin converting-enzyme
inhibitors (ACEI), angiotensin II receptor blockers (ARB), beta-
blockers (BB), aldosterone antagonists (AA), digoxin (DG), and
diuretics (DU) in reducing morbidity and mortality among
persons with heart failure (HF) has been well established in
clinical trials. Using the 2002 Medicare Current Beneﬁciary
Survey, we determined utilization of these drugs in the real-world
setting among community-dwelling older adults with HF.
METHODS: Community-dwelling, non-hospice beneﬁciaries
>65 years of age with a diagnosis code for HF (428.xx) were
included. Medication use was determined by beneﬁciary self-
report, documentation of prescription ﬁlls, and computer-
assisted personal interviews. Diagnosis codes were used to
identify beneﬁciaries without medical contraindications for each
drug, who were eligible to receive them. We further classiﬁed
beneﬁciaries into groups based on concomitant use of more than
one drug: ACEI or ARB and BB (group 1); ACEI or ARB, BB, and
AA (group 2); and ACEI or ARB, BB, AA, DG, and DU (group
3). RESULTS: We estimated that 1038, 590, 821, 1059, and 926
survey respondents were eligible to use an ACEI or ARB, BB, AA,
DG, or DU, respectively. Among those eligible, 55.9%, 44.1%,
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